Open AccessP011 A number needed to harm analysis of safety outcomes from randomized controlled trials of biologics and tofacitinib in ulcerative colitis
Author(s) -
KT Park,
Trevor Lissoos,
Greg Hather,
Aimee Blake,
Haridarshan Patel
Publication year - 2019
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000578116.03611.38
Subject(s) - vedolizumab , medicine , tofacitinib , adalimumab , golimumab , infliximab , ulcerative colitis , adverse effect , discontinuation , number needed to harm , number needed to treat , ustekinumab , randomized controlled trial , confidence interval , relative risk , rheumatoid arthritis , disease